Skip to main content
Top
Published in: Journal of Gastroenterology 2/2014

01-02-2014 | Original Article—Liver, Pancreas, and Biliary Tract

Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients

Authors: Yuki Ohishi, Makoto Nakamuta, Naoko Ishikawa, Ohki Saitoh, Hitomi Nakamura, Yoshihiro Aiba, Atsumasa Komori, Kiyoshi Migita, Hiroshi Yatsuhashi, Nobuyoshi Fukushima, Motoyuki Kohjima, Tsuyoshi Yoshimoto, Kunitaka Fukuizumi, Makoto Ishibashi, Takashi Nishino, Ken Shirabe, Akinobu Taketomi, Yoshihiko Maehara, Hiromi Ishibashi, Minoru Nakamura, PBC Study Group of NHOSLJ

Published in: Journal of Gastroenterology | Issue 2/2014

Login to get access

Abstract

Background

To identify the genetic factors involved in the pathogenesis of primary biliary cirrhosis (PBC), we focused on the organic cation transporter 1 (OCT1/SLC22A1), which is closely associated with phosphatidylcholine synthesis in hepatocytes.

Methods

We selected four (rs683369, rs2282143, rs622342 and rs1443844) OCT-1 single nucleotide polymorphisms (SNPs), and genotyped these SNPs using the TaqMan probe method in 275 Japanese PBC patients and 194 gender-matched, healthy volunteers as controls.

Results

The Chi-square test revealed that the rs683369 variant allele (G) was associated with insusceptibility to PBC development [P = 0.009, odds ratio (OR) 0.60, 95 % confidence interval (CI) 0.40–0.88] in an allele model, and that the rs683369 variant allele (G) was associated with jaundice-type progression in a minor allele dominant genotype model (P = 0.032, OR 3.10, 95 % CI 1.05–9.14). The OCT-1 rs2282143 variant (T) and rs622342 variant (C) were also associated with jaundice-type progression in a minor allele recessive genotype model (P = 0.0002, OR 10.58, 95 % CI 2.36–47.54, and P = 0.006, OR 7.84, 95 % CI 1.39–44.36, respectively). Furthermore, the association of OCT-1 rs683369 and rs622342 with susceptibility to jaundice-type progression was confirmed by a replication study with a distinct set of PBC patients who underwent liver transplantation.

Conclusions

The present study is the first report on the association of OCT-1 genetic polymorphisms with the overall development and jaundice-type progression of PBC.
Literature
2.
go back to reference Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007;45:118–27.PubMedCrossRef Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007;45:118–27.PubMedCrossRef
3.
go back to reference Gershwin ME, Ansari AA, Mackay IR, et al. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev. 2000;174:210–25.PubMedCrossRef Gershwin ME, Ansari AA, Mackay IR, et al. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev. 2000;174:210–25.PubMedCrossRef
4.
go back to reference Invernizzi P, Podda M, Battezzati PM, et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol. 2001;34:366–72.PubMedCrossRef Invernizzi P, Podda M, Battezzati PM, et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol. 2001;34:366–72.PubMedCrossRef
5.
go back to reference Nakamura M, Shimizu-Yoshida Y, Takii Y, et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol. 2005;42:386–92.PubMedCrossRef Nakamura M, Shimizu-Yoshida Y, Takii Y, et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol. 2005;42:386–92.PubMedCrossRef
6.
go back to reference Wesierska-Gadek J, Penner E, Battezzati PM, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology. 2006;43:1135–44.PubMedCrossRef Wesierska-Gadek J, Penner E, Battezzati PM, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology. 2006;43:1135–44.PubMedCrossRef
7.
go back to reference Worman HJ, Courvalin J-C. Antinuclear antibodies specific for primary biliary cirrhosis. Autoimmun Rev. 2003;2:211–7.PubMedCrossRef Worman HJ, Courvalin J-C. Antinuclear antibodies specific for primary biliary cirrhosis. Autoimmun Rev. 2003;2:211–7.PubMedCrossRef
9.
go back to reference Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005;128(2):297–303.PubMedCrossRef Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005;128(2):297–303.PubMedCrossRef
10.
go back to reference Selmi C, Invernizzi P, Zuin M, et al. Genes and (auto)immunity in primary biliary cirrhosis. Genes Immun. 2005;6:543–56.PubMedCrossRef Selmi C, Invernizzi P, Zuin M, et al. Genes and (auto)immunity in primary biliary cirrhosis. Genes Immun. 2005;6:543–56.PubMedCrossRef
11.
go back to reference Selmi C, Invernizzi P, Zuin M, et al. Genes and (auto) immunity in primary biliary cirrhosis. Genes Immun. 2005;6(7):543–56.PubMedCrossRef Selmi C, Invernizzi P, Zuin M, et al. Genes and (auto) immunity in primary biliary cirrhosis. Genes Immun. 2005;6(7):543–56.PubMedCrossRef
12.
go back to reference Brind AM, Bray GP, Portmann BC, et al. Prevalence and pattern of familial disease in primary biliary cirrhosis. Gut. 1995;36(4):615–7.PubMedCrossRef Brind AM, Bray GP, Portmann BC, et al. Prevalence and pattern of familial disease in primary biliary cirrhosis. Gut. 1995;36(4):615–7.PubMedCrossRef
13.
go back to reference Aiba Y, Nakamura M, Joshita S, et al. Genetic polymorphisms in CTLA4 and SLC4A2 are differentially associated with the pathogenesis of primary biliary cirrhosis in Japanese patients. J Gastroenterol. 2011;46(10):1203–12.PubMedCrossRef Aiba Y, Nakamura M, Joshita S, et al. Genetic polymorphisms in CTLA4 and SLC4A2 are differentially associated with the pathogenesis of primary biliary cirrhosis in Japanese patients. J Gastroenterol. 2011;46(10):1203–12.PubMedCrossRef
14.
go back to reference Tanaka A, Quaranta S, Mattalia A, et al. The tumor necrosis factor-alpha promoter correlates with progression of primary biliary cirrhosis. J Hepatol. 1999;30(5):826–9.PubMedCrossRef Tanaka A, Quaranta S, Mattalia A, et al. The tumor necrosis factor-alpha promoter correlates with progression of primary biliary cirrhosis. J Hepatol. 1999;30(5):826–9.PubMedCrossRef
15.
go back to reference Selmi C, Zuin M, Biondi ML, et al. Genetic variants of endothelial nitric oxide synthase in patients with primary biliary cirrhosis: association with disease severity. J Gastroenterol Hepatol. 2003;18(10):1150–5.PubMedCrossRef Selmi C, Zuin M, Biondi ML, et al. Genetic variants of endothelial nitric oxide synthase in patients with primary biliary cirrhosis: association with disease severity. J Gastroenterol Hepatol. 2003;18(10):1150–5.PubMedCrossRef
16.
go back to reference Poupon R, Ping C, Chrétien Y, et al. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol. 2008;49(6):1038–45.PubMedCrossRef Poupon R, Ping C, Chrétien Y, et al. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol. 2008;49(6):1038–45.PubMedCrossRef
17.
go back to reference Zhong B, Strnad P, Selmi C, et al. Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity. Hepatology. 2009;50(2):546–54.PubMedCentralPubMedCrossRef Zhong B, Strnad P, Selmi C, et al. Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity. Hepatology. 2009;50(2):546–54.PubMedCentralPubMedCrossRef
18.
go back to reference Kimura Y, Selmi C, Leung PS, et al. Genetic polymorphisms influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosis. Hepatology. 2005;41(1):55–63.PubMedCrossRef Kimura Y, Selmi C, Leung PS, et al. Genetic polymorphisms influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosis. Hepatology. 2005;41(1):55–63.PubMedCrossRef
19.
go back to reference Juran BD, Atkinson EJ, Schlicht EM, et al. Primary biliary cirrhosis is associated with a genetic variant in the 3′ flanking region of the CTLA4 gene. Gastroenterology. 2008;135(4):1200–6.PubMedCentralPubMedCrossRef Juran BD, Atkinson EJ, Schlicht EM, et al. Primary biliary cirrhosis is associated with a genetic variant in the 3′ flanking region of the CTLA4 gene. Gastroenterology. 2008;135(4):1200–6.PubMedCentralPubMedCrossRef
20.
go back to reference Donaldson P, Agarwal K, Craggs A, et al. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut. 2001;48(3):397–402.PubMedCrossRef Donaldson P, Agarwal K, Craggs A, et al. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut. 2001;48(3):397–402.PubMedCrossRef
21.
go back to reference Inamine T, Nakamura M, Kawauchi A, et al. A polymorphism in the integrin αV subunit gene affects the progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol. 2011;46(5):676–86.PubMedCrossRef Inamine T, Nakamura M, Kawauchi A, et al. A polymorphism in the integrin αV subunit gene affects the progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol. 2011;46(5):676–86.PubMedCrossRef
22.
go back to reference Mells GF, Floyd JA, Morley KI, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet. 2011;43(4):329–32.PubMedCentralPubMedCrossRef Mells GF, Floyd JA, Morley KI, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet. 2011;43(4):329–32.PubMedCentralPubMedCrossRef
23.
24.
go back to reference Hirschfield GM, Liu X, Han Y, et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet. 2010;42(8):655–7.PubMedCentralPubMedCrossRef Hirschfield GM, Liu X, Han Y, et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet. 2010;42(8):655–7.PubMedCentralPubMedCrossRef
25.
go back to reference Tanaka A, Invernizzi P, Ohira H, et al. Replicated association of 17q12-21 with susceptibility of primary biliary cirrhosis in a Japanese cohort. Tissue Antigens. 2011;78(1):65–8.PubMedCrossRef Tanaka A, Invernizzi P, Ohira H, et al. Replicated association of 17q12-21 with susceptibility of primary biliary cirrhosis in a Japanese cohort. Tissue Antigens. 2011;78(1):65–8.PubMedCrossRef
26.
go back to reference Liu X, Invernizzi P, Lu Y, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet. 2010;42(8):658–60.PubMedCentralPubMedCrossRef Liu X, Invernizzi P, Lu Y, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet. 2010;42(8):658–60.PubMedCentralPubMedCrossRef
27.
go back to reference Nakamura M, Nishida N, Kawashima M, et al. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet. 2012;91:721–8.PubMedCentralPubMedCrossRef Nakamura M, Nishida N, Kawashima M, et al. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet. 2012;91:721–8.PubMedCentralPubMedCrossRef
28.
go back to reference Pauli-Magnus C, Lang T, Meier Y, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics. 2004;14:91–102.PubMedCrossRef Pauli-Magnus C, Lang T, Meier Y, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics. 2004;14:91–102.PubMedCrossRef
29.
go back to reference de Vree JML, Jacquemin E, Sturm E, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA. 1998;95:282–7.PubMedCrossRef de Vree JML, Jacquemin E, Sturm E, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA. 1998;95:282–7.PubMedCrossRef
30.
go back to reference Jacquemin E, de Vree JML, Cresteil D, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology. 2001;120:1448–58.PubMedCrossRef Jacquemin E, de Vree JML, Cresteil D, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology. 2001;120:1448–58.PubMedCrossRef
31.
go back to reference Ohishi Y, Nakamura M, Iio N, et al. Single-nucleotide polymorphism analysis of the multidrug resistance protein 3 gene for the detection of clinical progression in Japanese patients with primary biliary cirrhosis. Hepatology. 2008;48(3):853–62.PubMedCrossRef Ohishi Y, Nakamura M, Iio N, et al. Single-nucleotide polymorphism analysis of the multidrug resistance protein 3 gene for the detection of clinical progression in Japanese patients with primary biliary cirrhosis. Hepatology. 2008;48(3):853–62.PubMedCrossRef
32.
go back to reference Smit JJ, Schinkel AH, Oude Elferink RP, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell. 1993;75:451–62.PubMedCrossRef Smit JJ, Schinkel AH, Oude Elferink RP, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell. 1993;75:451–62.PubMedCrossRef
33.
go back to reference Oude Elferink RP, Ottenhoff R, van Wijland M, et al. Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J Clin Invest. 1995;95:31–8. Oude Elferink RP, Ottenhoff R, van Wijland M, et al. Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J Clin Invest. 1995;95:31–8.
35.
go back to reference Oude Elferink RP, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Eur J Physiol. 2007;453:601–10. Oude Elferink RP, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Eur J Physiol. 2007;453:601–10.
36.
go back to reference Michel V, Yuan Z, Ramsubir S, et al. Choline transport for phospholipid synthesis. Exp Biol Med (Maywood). 2006;231(5):490–504. Michel V, Yuan Z, Ramsubir S, et al. Choline transport for phospholipid synthesis. Exp Biol Med (Maywood). 2006;231(5):490–504.
37.
go back to reference Sinclair CJ, Chi KD, Subramanian V, et al. Functional expression of a high affinity mammalian hepatic choline/organic cation transporter. J Lipid Res. 2000;41(11):1841–8.PubMed Sinclair CJ, Chi KD, Subramanian V, et al. Functional expression of a high affinity mammalian hepatic choline/organic cation transporter. J Lipid Res. 2000;41(11):1841–8.PubMed
38.
go back to reference Zeisel SH, Da Costa KA, Franklin PD, et al. Choline, an essential nutrient for humans. FASEB J. 1991;5(7):2093–8.PubMed Zeisel SH, Da Costa KA, Franklin PD, et al. Choline, an essential nutrient for humans. FASEB J. 1991;5(7):2093–8.PubMed
39.
go back to reference Nies AT, Koepsell H, Winter S, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009;50(4):1227–40.PubMedCrossRef Nies AT, Koepsell H, Winter S, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009;50(4):1227–40.PubMedCrossRef
40.
go back to reference Becker ML, Visser LE, van Schaik RH, et al. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 2009;9(4):242–7.PubMedCrossRef Becker ML, Visser LE, van Schaik RH, et al. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 2009;9(4):242–7.PubMedCrossRef
41.
go back to reference Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50(1):291–308.PubMedCrossRef Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50(1):291–308.PubMedCrossRef
43.
go back to reference van Helvoort A, Smith AJ, Sprong H, et al. MDR1 P-glycoprotein is a lipid translocase if broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell. 1996;87:507–17.PubMedCrossRef van Helvoort A, Smith AJ, Sprong H, et al. MDR1 P-glycoprotein is a lipid translocase if broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell. 1996;87:507–17.PubMedCrossRef
44.
go back to reference Jin HE, Hong SS, Choi MK, et al. Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynyl estradiol-induced cholestasis. Pharm Res. 2009;26(3):549–59.PubMedCrossRef Jin HE, Hong SS, Choi MK, et al. Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynyl estradiol-induced cholestasis. Pharm Res. 2009;26(3):549–59.PubMedCrossRef
45.
go back to reference Denk GU, Soroka CJ, Mennone A, et al. Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. Hepatology. 2004;39(5):1382–9.PubMedCrossRef Denk GU, Soroka CJ, Mennone A, et al. Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. Hepatology. 2004;39(5):1382–9.PubMedCrossRef
46.
go back to reference Becker ML, Visser LE, van Schaik RH, et al. OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics. 2011;12(1):79–82.PubMedCentralPubMed Becker ML, Visser LE, van Schaik RH, et al. OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics. 2011;12(1):79–82.PubMedCentralPubMed
47.
go back to reference Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev. 2010;62(1):1–96. Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev. 2010;62(1):1–96.
48.
go back to reference Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther. 2004;308(1):2–9.PubMed Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther. 2004;308(1):2–9.PubMed
49.
go back to reference Sakata T, Anzai N, Shin HJ, et al. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun. 2004;313(3):789–93.PubMedCrossRef Sakata T, Anzai N, Shin HJ, et al. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun. 2004;313(3):789–93.PubMedCrossRef
50.
go back to reference Shu Y, Leabman MK, Feng B, et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA. 2003;100(10):5902–7.PubMedCrossRef Shu Y, Leabman MK, Feng B, et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA. 2003;100(10):5902–7.PubMedCrossRef
51.
go back to reference Chen L, Takizawa M, Chen E, et al. Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J Pharmacol Exp Ther. 2010;335(1):42–50.PubMed Chen L, Takizawa M, Chen E, et al. Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J Pharmacol Exp Ther. 2010;335(1):42–50.PubMed
52.
go back to reference Nakamura M, Yasunami M, Kondo H, et al. Analysis of HLA-DRB1 polymorphisms in Japanese patients with primary biliary cirrhosis (PBC): the HLA-DRB1 polymorphism determines the relative risk of antinuclear antibodies for disease progression in PBC. Hepatol Res. 2010;40:494–504.PubMedCrossRef Nakamura M, Yasunami M, Kondo H, et al. Analysis of HLA-DRB1 polymorphisms in Japanese patients with primary biliary cirrhosis (PBC): the HLA-DRB1 polymorphism determines the relative risk of antinuclear antibodies for disease progression in PBC. Hepatol Res. 2010;40:494–504.PubMedCrossRef
Metadata
Title
Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients
Authors
Yuki Ohishi
Makoto Nakamuta
Naoko Ishikawa
Ohki Saitoh
Hitomi Nakamura
Yoshihiro Aiba
Atsumasa Komori
Kiyoshi Migita
Hiroshi Yatsuhashi
Nobuyoshi Fukushima
Motoyuki Kohjima
Tsuyoshi Yoshimoto
Kunitaka Fukuizumi
Makoto Ishibashi
Takashi Nishino
Ken Shirabe
Akinobu Taketomi
Yoshihiko Maehara
Hiromi Ishibashi
Minoru Nakamura
PBC Study Group of NHOSLJ
Publication date
01-02-2014
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 2/2014
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-013-0795-0

Other articles of this Issue 2/2014

Journal of Gastroenterology 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.